Glenmark Pharmaceuticals Ltd
NSE: GLENMARK BSE: 532296
₹2136.70
(0.58%)
Mon, 09 Mar 2026, 06:00 pm
Market Cap603.26B
PE Ratio56.64
Dividend0.23
Health Technology
Pharmaceuticals: Major
24.5KGlenmark Pharmaceuticals Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (12.7x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (13.5x coverage).
- Dividends per share have been stable in the past 10 years.
- Glenmark Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Glenmark Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Glenmark Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Glenmark Pharmaceuticals's earnings are expected to exceed the low risk growth rate next year.
- Glenmark Pharmaceuticals's revenue growth is expected to exceed the India market average.
- Cash flow for Glenmark Pharmaceuticals is expected to decrease over the next 2 years.
- Glenmark Pharmaceuticals's earnings are expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).
- Glenmark Pharmaceuticals's earnings growth is positive but not above the India market average.
- Glenmark Pharmaceuticals's net income is expected to increase but not above the 50% threshold in 2 years time.
- Glenmark Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.
- A decline in Glenmark Pharmaceuticals's performance (ROE) is expected over the next 3 years.
- Glenmark Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Glenmark Pharmaceuticals's revenue is expected to grow by 8.7% yearly, however this is not considered high growth (20% yearly).
health
- Glenmark Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Glenmark Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Glenmark Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (37.7%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.9x debt.
- Glenmark Pharmaceuticals's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (97.1% vs 59.7% today).
- Interest payments on debt are well covered by earnings (EBIT is 3.4x coverage).
- Glenmark Pharmaceuticals's level of debt (59.7%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Glenmark Pharmaceuticals board of directors is about average.
- Glenn's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Glenmark Pharmaceuticals management team is about average.
- Glenn's remuneration is higher than average for companies of similar size in India.
misc
- Glenmark Pharmaceuticals has significant price volatility in the past 3 months.
past
- Glenmark Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
- Glenmark Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Glenmark Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Glenmark Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Glenmark Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Glenmark Pharmaceuticals's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Glenmark Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.
- BSE:532296 is up 15.8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:532296 is up 15.8% outperforming the market in India which returned 8% over the past month.
- Glenmark Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Glenmark Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Glenmark Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Glenmark Pharmaceuticals is poor value based on expected growth next year.
- Glenmark Pharmaceuticals is overvalued based on earnings compared to the India market.
- 532296 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 532296 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800